Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Allergy: European Journal of Allergy and Clinical Immunology ; 76(SUPPL 110):455, 2021.
Article in English | EMBASE | ID: covidwho-1570397


Background: Under the restriction of direct access to specialized health care, COVID-19 pandemic, has created an “iceberg” regarding disease control data in severe Bronchial Asthma (BA). We aimed to evaluate indicators of asthma control, in severe persistent BA, consequences of pandemic and in-person visits limitations among this patient population. Method: A cross-sectional study, obtained data from 86 patients with yearly pre-pandemic hospitalizations, at the only tertiary hospital center for severe persistent BA in Albania. Descriptive data analysis was performed through anamnestic and clinical records. Standardized and validated questionnaires for inhalers adherence and asthma control, have been performed though phone interview during January 2021. Patients under treatment with biologic drugs (anti-IgE) and allergen specific immunotherapy have been excluded. Results: 64% were classified as high TH2 phenotype, predominating late-onset eosinophilic asthma (30.2%), and in low TH2 phenotype, with predominance of obesity associated asthma (18.6 %). 66,3 % were females with mean age of 49.3 ± 13.9. Overall Asthma Control Test (ACT= 19.5 ± 3.8), 43% controlled (20-25 points), with no statistically significant differences, between sex and phenotypes. Among early onset allergic asthma phenotype (25,6%), lower ACT score (18.5 ± 1.5) resulted in outdoor + indoor allergen polysensitization, compared to monosensitization (p < 0.05). Seasonal influenza vaccination rate was 16.2%, ACT score between vaccinated and unvaccinated groups, with significant difference (p = 0.03). Prevalence of confirmed COVID-19 was 15.1%, only 1,2% severe. ATC score, between confirmed or suspected post COVID-19 severe ABs and COVID-19 negative, was not statistically significant. Coexistence of sporadic and intentional nonadherence affected ACT score (p = 0.01), between controlled (ACT, 20-25) and uncontrolled group (ACT<20 points). Conclusion: Asthma control in severe persistent BA population was <50%, affected by sensitization profile, seasonal flu vaccination and type of non-adherence to inhalers. Differences of disease control in ACT score, were not statistically related with phenotype, sex or post COVID-19 infection condition. Particularly, Severe Persistent Bronchial Asthma needs a periodic specialist care to reach disease control and to lower the burden of indirect pandemic effects on disease progression.

European Journal of Neurology ; 28(SUPPL 1):692, 2021.
Article in English | EMBASE | ID: covidwho-1307807


Background and aims: Several case reports published recently have attributed numerous neurologic complications to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Guillain-Barre syndrome (GBS) and its variants, including facial diplegia are among some listed neurologic complications of COVID-19. In the background of the current COVID-19 pandemic a patient with Facial Diplegia related to acute inflammatory demyelinating polyneuropathy (AIDP) should be regarded as having a preceding or actual SARS-CoV-2 infection. Methods: We present the case of a patient with facial diplegia following a SARS-CoV-2 infection without prior relevant clinical history, managed conservatively with a favorable outcome. It is important to consider SARS-CoV-2 infection a potential trigger of AIDP, in cases presented with bilateral peripheral facial nerve paralysis. A high clinical suspicion will prompt to immediate management of these patients who will benefit from therapeutic management and hospitalization. Results: GBS can be the presenting disorder that evokes a diagnosis of a precedent COVID-19. Although the patient was asymptomatic from a respiratory perspective, her positive SARS-CoV-2 serological tests along with clinicalelectrophysiological findings were indicative of an antecedent SARS-CoV-2 infection directly responsible for the neurological complication. Conclusion: These results should be seen with careful adjustments and warrants future investigation since the knowledge of the pandemic of SARS-CoV-2 infection is rapidly changing. On the other hand our case adds on to those few other reported cases in the literature with the distinguishable feature of total neurological signs resolution with corticosteroid therapy. (Figure Presented).